Safinamide Mesylate
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Safinamide Mesylate is used to treat parkinson disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Mar 21, 2017, and the first generic was approved Jun 14, 2023. FDA's Orange Book lists 8 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $8 million on Safinamide Mesylate across 4,385 claims for 759 beneficiaries.
Safinamide Mesylate is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $36.33 to $36.46 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$36.33 – $36.46
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Monoamine Oxidase Type B Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing SAFINAMIDE MESYLATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
XADAGO 50 MG TABLET | $36.4591 per EA | — |
XADAGO 100 MG TABLET | $36.3258 per EA | — |
Frequently Asked Questions
What is Safinamide Mesylate used to treat?
Safinamide Mesylate is used to treat parkinson disease, per the National Library of Medicine's MED-RT classification.
When did Safinamide Mesylate become available as a generic?
FDA approved the first generic Safinamide Mesylate (ANDA) on Jun 14, 2023. The Orange Book currently lists 8 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Safinamide Mesylate?
In 2024, Medicare Part D spent $8 million on Safinamide Mesylate across 4,385 claims for 759 beneficiaries.
How many Safinamide Mesylate products are on the market?
The Safinamide Mesylate drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Safinamide Mesylate?
NADAC reference prices for Safinamide Mesylate range from $36.3258 to $36.4591 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Safinamide Mesylate?
1 manufacturer lists Safinamide Mesylate in NADAC. Ranked by number of NDCs, the largest are MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc. (2).